High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 tesla: Comparison with 1,000 s/mm 2for tumor conspicuity and discrimination of aggressiveness

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Tamada, Tsutomu ^a   Kanomata, Naoki ^a   Sone, Teruki ^a   Jo, Yoshimasa ^a   Miyaji, Yoshiyuki ^a   Higashi, Hiroki ^a   Yamamoto, Akira ^a   Ito, Katsuyoshi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PROSTATE CANCER; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; TUMOR INVASION; CANCER GRADING; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84900808332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096619     Document Type: Article

References (38)

1. American Cancer Society (2012) Cancer facts and figures 2012. Atlanta: American Cancer Society.
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
3. Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90: 162-173. (Pubitemid 34779587)
4. Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 90: 174-184. (Pubitemid 34779588)
5. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, et al. (2011) Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 261: 46-66.
6. Tamada T, Sone T, Jo Y, Yamamoto A, Ito K (2014) Diffusion weighted magnetic resonance imaging and its role in prostate cancer. NMR Biomed 27: 25-38.
7. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, et al. (1986) MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161: 401-407. (Pubitemid 17173295)
8. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, et al. (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168: 497-505.
9. Burdette JH, Elster AD, Ricci PE (1999) Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. Radiology 212: 333-339. (Pubitemid 29356549)
10. Provenzale JM, Engelter ST, Petrella JR, Smith JS, MacFall JR (1999) Use of MR exponential diffusion-weighted images to eradicate T2 "shine- through" effect. AJR Am J Roentgenol 172: 537-539. (Pubitemid 29082684)
11. Rosenkrantz AB, Hindman N, Lim RP, Das K, Babb JS, et al. (2013) Diffusionweighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. J Magn Reson Imaging 38: 694-700.
12. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, et al European Society of Urogenital Radiology (2012) ESUR prostate MR guidelines. 2012 Eur Radiol 22: 746-757.
13. 2). J Magn Reson Imaging 36: 198-205.
14. Koo JH, Kim CK, Choi D, Park BK, Kwon GY, et al. (2013) Diffusionweighted magnetic resonance imaging for the evaluation of prostate cancer: optimal B value at 3T. Korean J Radiol 14: 61-69.
15. Metens T, Miranda D, Absil J, Matos C (2012) What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T? Eur Radiol 22: 703-709.
16. Kim CK, Park BK, Kim B (2010) Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. AJR Am J Roentgenol 194: 1461-1469.
17. Ueno Y, Kitajima K, Sugimura K, Kawakami F, Miyake H, et al. (2013) Ultrahigh b-value diffusion-weighted MRI for the detection of prostate cancer with 3-T MRI. J Magn Reson Imaging 38: 154-160.
18. Ohgiya Y, Suyama J, Seino N, Hashizume T, Kawahara M, et al. (2012) Diagnostic accuracy of ultra-high-b-value 3.0-T diffusion-weighted MR imaging for detection of prostate cancer. Clin Imaging 36: 526-531.
19. van Oort IM, Bruins HM, Kiemeney LA, Knipscheer BC, Witjes JA, et al. (2010) The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy. Histopathology 56: 464-471.
20. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29: 1228-1242. (Pubitemid 41232997)
21. Tamada T, Sone T, Jo Y, Yamamoto A, Yamashita T, et al. (2008) Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. Radiology 248: 531-539.
22. Takenaka A, Hara R, Hyodo Y, Ishimura T, Sakai Y, et al. (2006) Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: a comparative study of 6 and 12 biopsy cores. Int J Urol 13: 10-14.
23. Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, et al. (1998) Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 206: 785-790. (Pubitemid 28128531)
24. Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, et al. (2011) Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol 197: 664-670.
25. Thoeny HC, Forstner R, De Keyzer F (2012) Genitourinary applications of diffusion-weighted MR imaging in the pelvis. Radiology 263: 326-342.
26. Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, et al. (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257: 715-723.
27. Noworolski SM, Vigneron DB, Chen AP, Kurhanewicz J (2008) Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging 26: 1071-1080.
28. Kim CK, Park BK, Han JJ, Kang TW, Lee HM (2007) Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. J Comput Assist Tomogr 31: 449-454. (Pubitemid 46849917)
29. Rosenkrantz AB, Sigmund EE, Johnson G, Babb JS, Mussi TC, et al. (2012) Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer. Radiology 264: 126-135.
30. Verma S, Rajesh A, Morales H, Lemen L, Bills G, et al. (2011) Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 196: 374-381.
31. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, et al. (2011) Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 197: 1382-1390.
32. Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, et al. (2011) Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 258: 488-495.
33. Thörmer G, Otto J, Reiss-Zimmermann M, Seiwerts M, Moche M, et al. (2012) Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol 22: 1820-1828.
34. Nagarajan R, Margolis D, Raman S, Sarma MK, Sheng K, et al. (2012) MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J Magn Reson Imaging 36: 697-703.
35. Doo KW, Sung DJ, Park BJ, Kim MJ, Cho SB, et al. (2012) Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol 22: 1812-1819.
36. Cookson MS, Fleshiner NE, Soloway SM, Fair WR (1997) Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 157: 559-562. (Pubitemid 27026838)
37. Kvåle R, Møller B, Wahlqvist R, Fosså SD, Berner A, et al. (2009) Concordant between Gleason score of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 103: 1647-1654.
38. Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS (2008) Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology 72: 177-182.